New antibody combo shows promise in early cancer trial

NCT ID NCT04958239

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 8 times

Summary

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose and see if the combination shrinks tumors. Participants are monitored for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 765179 (an antibody that may help the immune system fight cancer)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors and head and neck cancer.
What could go wrong: This is an early Phase I trial with a small number of participants, so it may not lead to a proven treatment. Side effects are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR INCURABLE, RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

AZ Groeninge

Kortrijk, 8500, Belgium
Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, 510095, China
Aichi Cancer Center Hospital

Aichi, Nagoya, 464-8681, Japan
Asan Medical Center

Seoul, 05505, South Korea
Austin Hospital

Heidelberg, Victoria, 3084, Australia
Avera Cancer Institute

Sioux Falls, South Dakota, 57105, United States
Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência

São Paulo, 01321-001, Brazil
Beverly Hills Cancer Center

Beverly Hills, California, 90211, United States
Border Cancer Hospital

Albury, New South Wales, 2640, Australia
CHA Bundang Medical Center

Seongnam, 13496, South Korea
CTR Georges-François Leclerc

Dijon, 21079, France
Centro Oncologico Internacional

Mexico City, 04700, Mexico
Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Clínica Universidad de Navarra

Pamplona, 31008, Spain
Erasmus Medisch Centrum-ROTTERDAM-50697

Rotterdam, 3015 GD, Netherlands
Fujian Cancer Hospital

Fuzhou, 350014, China
Fundación Santos y de la Garza Evia, I.B.P

Monterrey, 66278, Mexico
Gachon University Gil Medical Center

Incheon, 21565, South Korea
HOP Saint-André

Bordeaux, 33075, France
Hospital Clínico San Carlos

Madrid, 28040, Spain
Hospital Germans Trias i Pujol

Badalona, 08916, Spain
Hospital Sírio Libanês-São Paulo-68088

São Paulo, 01308050, Brazil
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Dr Jose Eleuterio Gonzalez

Monterrey, 64460, Mexico
Hunan Province Tumor Hospital

Changsha, 410013, China
ICESP - Instituto do Cancer do Estado de Sao Paulo

São Paulo, 01246-000, Brazil
INS Cancérologie Ouest Saint-Herblain

Saint-Herblain, 44805, France
Instituto Nacional de Cancerologia

México, 14080, Mexico
Istituto Nazionale IRCCS Tumori Fondazione Pascale

Naples, 80131, Italy
Kanagawa Cancer Center

Kanagawa, Yokohama, 241-8515, Japan
Kansai Medical University Hospital

Osaka, Hirakata, 573-1191, Japan
Kinghorn Cancer Centre

Darlinghurst, New South Wales, 2010, Australia
Klinikum Stuttgart

Stuttgart, 70174, Germany
Martin-Luther-Universität Halle-Wittenberg

Halle, 06120, Germany
Masaryk Memorial Cancer Institute

Brno, 65653, Czechia
NEXT Oncology-San Antonio-65273

San Antonio, Texas, 78229, United States
National Cancer Center Hospital East

Chiba, Kashiwa, 277-8577, Japan
Osaka International Cancer Institute

Osaka, Osaka, 541-8567, Japan
Shaare-Zedek Medical Center, Oncology Institute

Jerusalem, 9103102, Israel
Sourasky Medical Center

Tel Aviv, 6423906, Israel
The First Affiliated Hospital Of Bengbu Medical College

Bengbu, 233004, China
The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Townsville Hospital

Douglas, Queensland, 4814, Australia
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430022, China
Universitair Ziekenhuis Antwerpen

Edegem, 2650, Belgium
University of Arizona

Tucson, Arizona, 85719, United States
Universitätsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany
VU University Medical Center

Amsterdam, 1081HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.